NHD Global
Metabolic Research · NNMT
Scientific Dossier
5-Amino-1MQ is a cell-permeable small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Published preclinical work connects NNMT inhibition with lower 1-MNA, higher intracellular NAD+ and SAM, reduced lipid accumulation in adipocytes, lower adiposity in diet-induced obese mice and stronger muscle regeneration in aged mice. Human efficacy, safety and dosing have not been established.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
5-Amino-1MQ suppressed lipid accumulation during 3T3-L1 adipocyte differentiation and altered NNMT-linked metabolites.
Reported at laboratory concentrations in cultured cells; not evidence of fat loss in humans.
Read the primary studyIn an 11-day diet-induced-obesity mouse experiment, treated animals showed about 5.1% weight loss, about 35% lower epididymal fat-pad mass and more than 30% smaller adipocytes versus controls.
The reported protocol was a controlled mouse study and must not be interpreted as human dosing guidance.
Read the primary studyThe same mouse experiment reported approximately 30% lower plasma total cholesterol while cumulative food intake was not significantly different.
Model-specific metabolic outcome; no human lipid-lowering claim is established.
Read the primary studyAged mice treated after muscle injury showed increased muscle-stem-cell activity, nearly two-fold greater regenerating myofiber area and roughly 70% higher peak torque than controls.
Preclinical regeneration model; not proof of improved strength or recovery in people.
Read the primary studyThe study measured membrane permeability, enzyme selectivity, adipocyte metabolites and lipogenesis, then assessed body weight, white adipose tissue and cholesterol in diet-induced obese mice.
These endpoints support preclinical investigation of NNMT inhibition. The paper did not test weight-loss efficacy in people.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Small-molecule research compound · 5 mg/vial nominal · 10-vial pack · chemical form, identity and assay controlled by lot specification.
Request by lot: CoA, identity and assay summary
Small-molecule research compound · 10 mg/vial nominal · 10-vial pack · chemical form, identity and assay controlled by lot specification.
Request by lot: CoA, identity and assay summary
Small-molecule research compound · 50 mg/vial nominal · 10-vial pack · chemical form, identity and assay controlled by lot specification.
Request by lot: CoA, identity and assay summary
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Published work evaluated NNMT-related metabolites and lipogenesis in cultured adipocytes. This is mechanistic laboratory evidence, not a human outcome.
View primary recordThe same publication reported physiological measurements in a high-fat-diet mouse model. Findings remain preclinical and model-specific.
View primary recordA validated LC-MS/MS assay was applied to rat plasma and urine pharmacokinetic work. It does not establish human pharmacokinetics.
View primary recordThird-party publications selected for direct relevance.
National Center for Biotechnology Information. PubChem CID 950107; record modified July 25, 2026.
Neelakantan H, et al. Biochemical Pharmacology. 2018;147:141–152. PMID 29155147 · DOI 10.1016/j.bcp.2017.11.007
Neelakantan H, et al. Biochemical Pharmacology. 2019. PMID 30753815 · DOI 10.1016/j.bcp.2019.02.008
Awosemo O, et al. Journal of Pharmaceutical and Biomedical Analysis. 2021;204:114255. PMID 34304009 · DOI 10.1016/j.jpba.2021.114255
J. Med. Chem. 2017. PMID 28548833 · DOI 10.1021/acs.jmedchem.7b00389.
Concise answers for researchers comparing identity, evidence and catalog variants.
5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide methylation, 1-MNA formation and the balance of NAD+ and methyl-donor metabolism.
No. Despite often appearing in peptide research catalogs, 5-Amino-1MQ is a methylquinolinium small molecule and contains no peptide chain.
Published preclinical studies reported NNMT inhibition, lower intracellular 1-MNA, higher NAD+ and SAM, reduced adipocyte lipid accumulation, lower adiposity measurements in diet-induced-obese mice and improved muscle regeneration after injury in aged mice.
No established human clinical efficacy, safety profile or dosing regimen is available. Results on this page are limited to biochemical, cell and animal research.
Some references describe the free 5-amino-1-methylquinolinium cation, while supplied research material may be a specific counter-ion salt. The lot-specific specification and COA must control the identity, formula and molecular weight used for procurement.
They are catalog pack-size variants within the same product family. Select the required nominal amount and request the corresponding lot-specific COA before ordering.
Knowledge center
Owned educational content connected to this family.
A source-led review of 5-Amino-1MQ as an NNMT inhibitor, separating enzyme, cell and mouse findings from claims that have not been demonstrated in humans.
Updated August 28, 2026
A practical laboratory guide to checking 5-Amino-1MQ identity, purity language, analytical methods and lot-specific documentation without confusing a catalog listing with a published study…
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Published-study results are tied to the linked records and kept separate from catalog-lot claims. Imported purity, storage and document-availability templates have been removed pending product- and lot-specific confirmation.
Technical procurement
Selected: 10AM · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
